A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis
Autor/innen
- J. Esparza-Gordillo
- H. Schaarschmidt
- L. Liang
- W. Cookson
- A. Bauerfeind
- M.A. Lee-Kirsch
- K. Nemat
- J. Henderson
- L. Paternoster
- J.L. Harper
- E. Mangold
- M.M. Nothen
- F. Rüschendorf
- T. Kerscher
- I. Marenholz
- A. Matanovic
- S. Lau
- T. Keil
- C.P. Bauer
- M. Kurek
- A. Ciechanowicz
- M. Macek
- A. Franke
- M. Kabesch
- N. Hubner
- G. Abecasis
- S. Weidinger
- M. Moffatt
- Y.A. Lee
Journal
- Journal of Allergy and Clinical Immunology
Quellenangabe
- J Allergy Clin Immunol 132 (2): 371-377
Zusammenfassung
BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease. Previous studies have revealed shared genetic determinants among different inflammatory disorders, suggesting that markers associated with immune-related traits might also play a role in AD. OBJECTIVE: We sought to identify novel genetic risk factors for AD. METHODS: We examined the results of all genome-wide association studies from a public repository and selected 318 genetic markers that were significantly associated with any inflammatory trait. These markers were considered candidates and tested for association with AD in a 3-step approach including 7 study populations with 7130 patients with AD and 9253 control subjects. RESULTS: A functional amino acid change in the IL-6 receptor (IL-6R Asp358Ala; rs2228145) was significantly associated with AD (odds ratio [OR], 1.15; P = 5 x 10(-9)). Interestingly, investigation of 2 independent population-based birth cohorts showed that IL-6R 358Ala specifically predisposes to the persistent form of AD (ORpersistent AD = 1.22, P = .0008; ORtransient AD = 1.04, P = .54). This variant determines the balance between the classical membrane-bound versus soluble IL-6R signaling pathways. Carriers of 358Ala had increased serum levels of soluble IL-6R (P = 4 x 10(-14)), with homozygote carriers showing a 2-fold increase. Moreover, we demonstrate that soluble IL-6R levels were higher in patients with AD than in control subjects (46.0 vs 37.8 ng/mL, P = .001). Additional AD risk variants were identified in RAD50, RUNX3, and ERBB3. CONCLUSION: Our study supports the importance of genetic variants influencing inflammation in the etiology of AD. Moreover, we identified a functional genetic variant in IL6R influencing disease prognosis and specifically predisposing to persistent AD.